SUMMARY Evaluation of the costs and benefits of public sector programmes is necessary to plan the optimum uses for society's resources. Here the benefits of screening for open neural tube defects are examined, and the most appropriate methodological approach to their valuation is discussed in the context of the possible provision by the National Health Service of a routine prenatal screening programme. It is argued that, in measuring the benefits of screening, previous evaluations have adopted an approach that is rather unsatisfactory from the standpoint of economic methodology. An attempt is therefore made here to show the effect that adopting a more appropriate approach would have on the estimated value of the benefit of routine screening. The effect is found to be a substantial increase in its estimated value.
The recent Select Committee report on perinatal mortality' included the recommendation that each regional health authority of the NHS should consider the establishment of a mass-screening programme for the prenatal detection and abortion of fetuses affected by open neural tube defect. Both this and the earlier report by the Working Group on Screening for Neural Tube Defects,2 chaired by Sir Douglas Black, have provoked discussion3 of the question of whether or not trying to prevent the birth of all affected infants, by terminating pregnancy, would benefit society as a whole. Cost-benefit analysis can usefully help attempts to reach an answer to this question. 4 In all parts of the public sector, planning, aided by economic tools such as cost-benefit analysis, is necessary to produce efficient allocation of resources.' Efficiency in the NHS means allocating resources so as to secure the maximum benefit, in terms of the relief of suffering caused by sickness and disability, that is attainable within the constraint of the NHS's lhnited budget. This implies that the benefit derived from each and every treatment or service offered should be at least as great as the opportunity cost of obtaining it (opportunity cost being the cost of foregoing the alternative benefits that could be derived from the resources consumed5 6). Hence under the cost-benefit criterion resources would be allocated to a screening programme and the programme extended to new client groups only if the benefits were equal to or greater than the opportunity cost.
Previously both a cost-benefit analysis of screening for spina bifida cystica7 and analysis of the cost-effectiveness to the public sector of screening for neural tube defects8 have suggested that the cost of a screening programme would be outweighed by the benefits that it would bring, except perhaps in areas of low incidence of neural tube defect. This paper extends the methodology of measuring the benefits of such screening programmes by comparing the costs and benefits of the cohort of handicapped individuals who would be born if there were no screening programme, with the costs and benefits of the cohort of "replacement" non-handicapped individuals who would probably be born if there were a screening programme. It is from the difference between these two that the cost of the screening programme itself has been subtracted to arrive at an estimate of its expected net benefit. This contrasts with the methodology of previous studies, which simply compared the costs of a handicapped individual with the costs of a non-handicapped individual (here termed the "excess cost" method) from which was subtracted the cost of the screening programme.
The methodology of the present study allows, firstly, for the fact that replacement can be less than 100%; secondly, that individuals handicapped by has been obtained from usage data in previous studies of the handicapped7 8 21 22 and from official surveys.23-28 Goods and services provided publicly, other than those specifically mentioned in category (b), have been assumed either to cost a negligible amount per consumer or to be "public goods" that can only be consumed collectively-for instance, defence-which means that the "marginal" or incremental cost of their consumption by either cohort is zero.
Any unmarketed output produced has been assumed to be completely consumed by the producer implying that the benefit of the output and the cost of the consumption to the rest of society is zero and therefore these benefits and costs (categories (c) and (f)) have been omitted from the calculations. A case where this assumption is obviously incorrect is that of household services produced by women. For most women personal consumption of unmarketed household services will be less than the output they produce. It has been implicitly assumed, however, that the remaining output is consumed by husbands within the same cohort to ensure that when the costs of men and women are combined the output and consumption of unmarketed goods and services sum to zero and can be excluded from the analysis.
As a minimum estimate of the intangible benefit, net of intangible cost, that children bring to their parents, the financial costs to parents of having a non-handicapped child have been calculated on the principle that if parents are freely prepared to pay these costs then they must receive at least as much net psychological benefit. Various reductions of this value have then been used to estimate the lesser psychological benefit of having a handicapped child.29 As a minimum estimate, a net value of zero has been used, implying that the psychological costs and benefits of having a handicapped child are equal. As a middle value, an estimate of 50% of the value imputed to the non-handicapped has been used. As a maximum estimate, a net value equal to that imputed to the non-handicapped has been used, implying that, in terms of psychological costs and benefits, parents are indifferent between having a handicapped and a non-handicapped child. Other values in categories (g) and (h) have not been calculated.
Results
One would expect the net cost to society of any given number of individuals handicapped by open spina bifida to be greater than the net cost to society of an equal number of non-handicapped individuals of the same age and indeed the results of the present study confirm this.2" As explained earlier, however, simply taking the excess cost of the former over the latter is not a wholly appropriate method of measuring the benefit of a screening programme. When allowance is made for different rates of replacement, the delay of replacement, and the different survival experience of Estimated benefit under different assumptions compared with estimated cost of a screening programme.
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The "correct" rate at which to discount future costs and benefits is still a matter of debate,6 so a range of rates, including the public sector test discount rate of 7% recommended by the Treasury, has been used to show the sensitivity of the findings to different rates. The results suggest that the net tangible benefit (at November 1979 prices) from avoiding the birth of a nominal cohort of 100 individuals handicapped by open spina bifida ranges with no replacement from about £2m at a 4% discount rate to about £1 -4m at a 10% discount rate; with 50% replacement from about £1-7m to about L1m; with complete replacement from about £15m to about £0-7m.
These results are compared in table 4 with those obtained using the excess cost method (which assumes complete and immediate replacement by unaffected fetuses). The excess cost method underestimates the benefit by between £0-3m (4% discount rate) and £0-im (10% discount rate) or by between 18% and 13%. The difference is clearly much greater if replacement is less than 100%. Table 5 shows the contrast to be more pronounced when an estimate of the psychological cost suffered by parents is included. If, for example, replacement is complete and it is assumed that the psychological costs and benefits to parents of having a handicapped child are equal, the minimum estimated benefit now ranges from about £1 * 9m (4% discount rate) to about £1 1 m (10% discount rate). The amount by which the excess cost method underestimates the benefit is increased to between £0-7m and £0-4m or by between 37% and 41%.
To programme must not be ignored. Even such crude estimates of intangible costs and benefits as those presented here can make a significant difference to the results of a cost-benefit analysis.
The method used here would also be appropriate for measuring the benefits of other screening programmes for the prenatal detection of fetal malformations, where detection is followed by termination of pregnancy and a replacement pregnancy is likely, as with the routine provision of prenatal diagnosis of Down's syndrome.32 Although these and similar33 evaluations may be criticised on the methodological grounds discussed here, they nevertheless represent an important contribution to the rational planning of resource use in health services. Such planning is indispensable if the NHS, from its limited budget, is to attempt to maximise the benefits that it produces for society.34 
